Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Fibrotic Interstitial Lung Disease
Interventions
DRUG

Exertional Oxygen

Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes

BEHAVIORAL

Education and Support

Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.

Trial Locations (1)

T6G2R3

RECRUITING

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
collaborator

Alberta Boehringer Ingelheim Collaboration

UNKNOWN

lead

University of Alberta

OTHER